BTAI Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - BioXcel Therapeutics Inc - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 2.63 USD 0.77%

Updated:

Section:

Wall Street
Price Targets

Wall Street analysts forecast BTAI stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BTAI is 10.71 USD with a low forecast of 3.54 USD and a high forecast of 25.2 USD.

BTAI Lowest Forecast

Wall Street Target

BTAI Average Forecast

Wall Street Target

BTAI Highest Forecast

Wall Street Target

34% Upside

307% Upside

858% Upside

The latest public price target was made on Apr 15, 2024 by Raghuram Selvaraju from H.C. Wainwright , who expects BTAI stock to rise by 280% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst	Price Target	Date	Article
Raghuram Selvaraju H.C. Wainwright	10 USD Upside 280%	1 week ago Apr 15, 2024	BioXcel Therapeutics (BTAI) PT Lowered to $10 at H.C. Wainwright StreetInsider
Graig Suvannavejh Mizuho Securities	4 USD Upside 52%	8 months ago Aug 15, 2023	Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy Benzinga

Price Target	10 USD
Upside/Downside	280%

Price Target	4 USD
Upside/Downside	52%

Yili Chuanning Biotechnology Co Ltd

8% Upside

Exact Sciences Corp

57% Upside

HOOKIPA Pharma Inc

437% Upside

Adimmune Corp

29% Upside

Yili Chuanning Biotechnology Co Ltd

8% Upside

Exact Sciences Corp

57% Upside

HOOKIPA Pharma Inc

437% Upside

Adimmune Corp

29% Upside

Tango Therapeutics Inc

141% Upside

Niox Group PLC

16% Upside

United Therapeutics Corp

27% Upside

Alvotech SA

19% Upside

Revenue
Forecast

The compound annual growth rate of BioXcel Therapeutics Inc's revenue for the next 3 years is 216%.

N/A

216%

N/A

N/A

What are analyst estimates?

Operating Income
Forecast

N/A

N/A

-4%

What are analyst estimates?

Net Income
Forecast

N/A

N/A

-25%

What are analyst estimates?

See Also

Relative Valuation

Wall Street Estimates

Profitability Analysis

Solvency Analysis

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

According to Wall Street analysts, the average 1-year price target for BTAI is 10.71 USD with a low forecast of 3.54 USD and a high forecast of 25.2 USD.

The compound annual growth rate of BioXcel Therapeutics Inc's revenue for the next 3 years is 216%.

Join more than 132,300+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.